Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan-Reference-Cited by-同舟云学术

Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan

Published:2015-02-10 Issue:4 Volume:61 Page:1154-1162
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Chiang Chun-Ju¹²,Yang Ya-Wen¹²,Chen Jin-De³,You San-Lin²⁴⁵,Yang Hwai-I⁴,Lee Mei-Hsuan⁶,Lai Mei-Shu¹²,Chen Chien-Jen¹²⁴

Affiliation:

1. Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University; Taipei Taiwan

2. Taiwan Cancer Registry; Taipei Taiwan

3. Department of Internal Medicine, Bei-Hu Branch; National Taiwan University Hospital; Taipei Taiwan

4. Genomics Research Center, Academia Sinica; Taipei Taiwan

5. Department of Public Health, College of Medicine; Fu-Jen Catholic University; New Taipei Taiwan

6. Institute of Clinical Medicine, College of Medicine, National Yang-Ming University; Taipei Taiwan

Publisher

Wiley

Subject

Hepatology

Reference37 articles.

1. Hepatocellular carcinoma in Taiwan;Chen;Hepatol Res,2007

2. Centers for Disease Control, Department of Health, Taiwan, ROC. Annual report 2012 http://www.cdc.gov.tw/uploads/files/201208/67addf76-0493-4d7b-aa72-cd51beff6654.pdf

3. Natural history of chronic hepatitis B REVEALed;Chen;J Gastroenterol Hepatol,2011

4. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C;Huang;J Clin Oncol,2011

5. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B carrier-mothers;Chen;JAMA,1987

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC;Clinical Gastroenterology and Hepatology;2024-06

2. Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years;Scientific Reports;2024-04-20

3. Chemotherapeutics;Pharmacognosy;2024

4. Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study;Anticancer Research;2023-09-29

5. Viral Status and Treatment Efficacy in Recurrent Hepatocellular Carcinoma After Primary Resection;Journal of Gastrointestinal Surgery;2023-05-25